NHD Global
Longevity & Bioregulators · Source-reviewed dossier
Source-Reviewed Research Dossier
Thymosin alpha-1 is a peptide studied for immune regulation. Researchers investigate how it changes communication between immune cells, especially when responses are unbalanced. The linked reviews discuss infection, immune-compromised states, vaccine-response research and adjunctive sepsis treatment. These involve different patients and outcomes, so results cannot be combined into a general immune-boosting claim. Reviews summarize earlier studies rather than directly testing NHD material. Clinical preparations and laboratory research products need to be distinguished.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2020 review summarized thymosin alpha-1 biology and reported uses across immune-compromised and infectious-disease settings.
The review does not support unrestricted use or interchangeability of materials.
Read the primary studyA 2018 review assessed thymosin alpha-1 as an adjunct in sepsis and discussed the limits of the available clinical literature.
Adjunctive sepsis evidence is not a general immune-health claim.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The review does not support unrestricted use or interchangeability of materials.
View primary recordAdjunctive sepsis evidence is not a general immune-health claim.
View primary recordThird-party publications selected for direct relevance.
Dominari A, et al. World J Virol. 2020. PMID 33362999.
Clinical review. 2018. PMID 30063866.
Concise answers for researchers comparing identity, evidence and catalog variants.
Reviews report immune-cell signalling changes and some positive results as an added treatment in sepsis and other infections. Outcomes vary by patient group and protocol. These are summaries of past studies, not tests of this catalog material. They do not show a general immune boost or prove that any research vial equals a clinical product.
Clinical studies used specific finished pharmaceutical products given by particular routes to particular patients. A research research material is a different article. Its identity is defined by catalog and lot documents, not those publications. Nothing in the literature confirms that a catalog lot matches any studied medicine.
Reviews cover both laboratory and clinical studies, with heterogeneous indications and study quality.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not…
Updated October 1, 2026
Thymalfasin is synthetic thymosin alpha-1: a defined 28-amino-acid peptide with an N-terminal acetyl group. Sequence and acetylation are part of identity, not optional catalog…
Updated October 1, 2026
Seeing the words “cancer research” makes it easy to think of directly killing tumors. This scoping review of thymosin alpha-1 mainly focuses on how…
Updated October 12, 2026
Use a small weight example to separate water content from peptide content.
Updated October 15, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: TA5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
